Document Detail

Acute myeloid leukemia: a classification and treatment update.
MedLine Citation:
PMID:  14603550     Owner:  NLM     Status:  MEDLINE    
Approximately 11,000 Americans will be diagnosed with acute myeloid leukemia (AML) in 2003, and about 75% ultimately will die from the disease. Despite significant advances in understanding biologic, molecular, and cytogenetic aspects of this malignancy, several other areas remain poorly understood. During the 1990s, significant advances in the characterization of this condition have shown that AML affects elderly patients more frequently. Treatment of patients in this age group poses a greater challenge partly because of increased tumor resistance and the presence of multiple medical comorbidities that may contraindicate therapy. New therapeutic approaches are promising and have renewed enthusiasm and optimism among patients and healthcare providers. Future treatment strategies for patients with AML most likely will include combinations of biologic agents with defined molecular targets (e.g., monoclonal antibodies, retinoids, hypomethylating agents, tyrosine kinase inhibitors).
Christine Scura Iovino; Luis H Camacho
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  7     ISSN:  1092-1095     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:    2003 Sep-Oct
Date Detail:
Created Date:  2003-11-07     Completed Date:  2003-12-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  535-40     Citation Subset:  N    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm
Hematopoietic Stem Cell Transplantation
Leukemia, Myeloid, Acute / classification*,  epidemiology,  therapy*
Patient Selection
Protein-Tyrosine Kinases / antagonists & inhibitors
Remission Induction / methods
Retinoids / therapeutic use
Salvage Therapy
Severity of Illness Index
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Retinoids; EC Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Facilitating exercise adherence for patients with multiple myeloma.
Next Document:  Diffuse malignant pleural mesothelioma: Part II. Symptom management.